Q4 2025 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Tarsus Pharmaceuticals Inc (TARS) reported over $450 million in net sales for 2025, highlighting strong financial performance.
- XDEMVY, the first FDA-approved therapeutic for Demodex blepharitis, has helped over 0.5 million patients, showcasing its real-world impact.
- The company anticipates XDEMVY reaching blockbuster status with sales potential exceeding $2 billion.
- Tarsus Pharmaceuticals Inc (TARS) plans to expand its pipeline by targeting 1 to 2 new programs per year, ensuring sustained growth.
- The company has strong financial flexibility with approximately $419 million in cash, cash equivalents, and marketable securities.
- Operating expenses were high at $522.3 million, driven by commercial investments for the XDEMVY launch.
- The company expects first-quarter 2026 revenues to be flat or slightly below Q4 2025 due to typical seasonality and deductible resets.
- Gross to net discount pressures are anticipated in Q1 2026, affecting revenue projections.
- The company faces challenges in expanding its market internationally, with differences in pricing and reimbursement dynamics.
- There is uncertainty regarding the exact timeline for achieving the $2 billion peak sales target for XDEMVY.
Good afternoon, and welcome to Tarsus Fourth Quarter and Full Year 2025 Financial Results Conference Call. As a reminder, this call is being recorded. (Operator Instructions).
At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.
Thank you the forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
With that, I'll turn the call over to Bobby.
Good afternoon, and thank you for joining us. 2025 was a breakout year for Tarsus and for XDEMVY.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
